<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976794</url>
  </required_header>
  <id_info>
    <org_study_id>2898</org_study_id>
    <nct_id>NCT00976794</nct_id>
  </id_info>
  <brief_title>Efficacy of Combined Treatment for Young Bipolar I Disorder</brief_title>
  <acronym>LICAVAL</acronym>
  <official_title>Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the combination of lithium and
      carbamazepine compared with lithium and valproate treating young bipolar patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After the diagnostic assessments, the patients are allocated for one of the following groups
      of treatment:

      Group I: lithium + valproic acid

      Group II: lithium + carbamazepine

      Patients will be followed up for 8 weeks in phase I (acute treatment), 6 months in phase II
      (continuation treatment) and 12 months in phase III (maintenance treatment). Scales raters
      will be blind to the treatment.

      During phase II and III will continue only patients that achieve response, measured according
      to initial symptoms score in phase I.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study.</measure>
    <time_frame>August 2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome will include the proportion of patients that had response but not remission to each treatment at the end of each phase of the study</measure>
    <time_frame>August 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>lithium plus carbamazepine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of the two drugs in standard dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lithium plus valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combination of the two drugs in standard dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium plus carbamazepine</intervention_name>
    <description>Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability</description>
    <arm_group_label>lithium plus carbamazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium plus valproate</intervention_name>
    <description>Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability.</description>
    <arm_group_label>lithium plus valproate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Bipolar Disorder, type I, in current episode (manic/hypomanic,
             mixed or depression)

          -  The patient or his (her) legal representative should understand the nature of the
             study and sign the Informed Consent.

        Exclusion Criteria:

          -  Schizophrenia or schizoaffective disorder

          -  Mental retardation

          -  Unstable clinical diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Psychiatry - University of São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: a critical review. J Affect Disord. 2005 May;86(1):1-10. Review.</citation>
    <PMID>15820265</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Ricardo Alberto Moreno, M.D., Ph.D.</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>BD I</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

